On a summer afternoon when millions of Americans head outdoors for longer days in the sun, researchers at NYU Langone's Perlmutter Cancer Center unveiled a breakthrough that could rewrite the prognosis for one of skin cancer's most dangerous forms. Their personalized mRNA vaccine, combined with immunotherapy, cuts the risk of melanoma recurrence by nearly half over five years — a finding that experts say could reshape cancer treatment far beyond melanoma itself.
The stakes are substantial. Melanoma affects approximately 112,000 Americans annually and remains the deadliest form of skin cancer. Within five years of initial treatment, about half of all melanoma patients face recurrence. That's where this new approach offers tangible hope.
The treatment pairs Moderna and Merck's personalized mRNA vaccine, called intismeran autogene, with Merck's established immunotherapy drug Keytruda. In a clinical trial of 157 patients with advanced melanoma, the results were striking: after five years, approximately 69% of patients receiving both treatments remained cancer-free, compared to just 49% of those treated with Keytruda alone. The combination also reduced the risk of cancer spreading to other parts of the body by 59%.
What makes this vaccine distinctive is its personalization. Scientists sequence genetic material from each patient's specific tumor, identifying unique proteins called neoantigens that appear on cancer cell surfaces. They then design a custom vaccine to train the immune system's T-cells to recognize and attack these targets. The process takes four to six weeks after surgery, with patients receiving up to nine vaccine doses over several months, coordinated with their immunotherapy.
Unlike many cancer treatments notorious for severe side effects, the vaccine showed low toxicity. Patients reported flu-like symptoms — chills and headaches — similar to what many experienced with COVID vaccines, and these lasted only a few days. This safety profile could prove critical for patient adoption and quality of life during treatment.
The research was presented Monday at the American Society of Clinical Oncology's annual meeting and published in the Journal of Clinical Oncology. Yet researchers acknowledge they're working from a smaller trial. Data from a larger Phase 3 study involving 1,000 patients across multiple countries is now being analyzed. If those results prove equally promising, the implications could be transformative.
Dr. Shailender Bhatia of Fred Hutch Cancer Center, who was not involved in the research, captured the significance in his remarks to NBC News: "We have tried to use vaccines in cancer therapy for decades, but the efficacy has not been clinically relevant in phase 3 trials to date. If this is successful, this will open up a new field that will be relevant not just to melanoma, but many other cancers."
That expansive potential — a vaccine framework that could eventually apply to multiple cancer types — is what propels this moment beyond a single advance. The approach harnesses the immune system's own capacity to recognize and eliminate cancer cells, a principle that researchers believe could scale across different malignancies.
As summer peaks and UV exposure climbs, prevention remains essential. The American Cancer Society continues to emphasize broad-spectrum sunscreen, seeking shade during peak hours, and protective clothing. But now, for those who do develop melanoma, this personalized vaccine approach offers evidence that outcomes once considered inevitable might be substantially altered. The next months of Phase 3 data will determine whether this promise becomes standard care.